Pharmaceutical

Debiopharm and Alkyon link for radioligand therapies development

Debiopharm has entered a co-research agreement with Alkyon Therapeutics to explore the potential of developing targeted RLTs.

Jun 15, 2025 - 06:00
Debiopharm and Alkyon link for radioligand therapies development
Debiopharm has entered a co-research agreement with Alkyon Therapeutics to explore the potential of developing targeted RLTs.
Read the original article

Tags:

Previous Article

Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger adults

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: The FDA’s approval of a new gene therapy for Duchenne muscular dystrophy won’t help me — but it gives me hope

Opinion: The FDA’s approval of a new gene therapy for D...

Jun 22, 2023

Invivyd receives FDA IND clearance for VYD222 to prevent Covid-19

Invivyd receives FDA IND clearance for VYD222 to preven...

Apr 26, 2023

Process automation and equipment

Process automation and equipment

May 23, 2024